MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: www.youtube.com/msviewsandnews -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~


Saturday, December 24, 2011

Experimental multiple sclerosis drug, Alemtuzumab (LEMTRADA(TM*) shows promise


Remember after watching the video, that this medication is still in trial studies


BY SONYA COLBERG scolberg@opubco.com    
Published: December 24, 2011

Jennifer Garner was getting desperate.

She wasn't even 40, yet found herself unable to see clearly and having to use her cane more frequently as the confounding numbness returned to the left half of her body. She had to be hospitalized three times over a short time period.

In 2004, an MRI showed telltale lesions in her brain.

After more testing, the physician assistant and mother began taking the drug Rebif for multiple sclerosis.
But after a couple of years, her body began rejecting the medication and the lesions worsened.

Her doctor, Gabriel Pardo, told her about various MS studies under way and suggested she use her medical background to choose a medication to try. She settled on a new, promising drug called alemtuzumab.

“From August to December, when I got the treatment, I had worsened dramatically. I can't even imagine what kind of shape I would be in, whether I would even be walking,” Garner said.

“Instead, I still have a full-time job, have my own business and two children. I can't afford to not be walking,” she said.
Positive results
If the new drug continues to live up to recent results, it may offer new hope for MS patients.

Read more: http://newsok.com/experimental-multiple-sclerosis-drug-shows-promise/article/3634670#ixzz1hfBucdoM



WATCH VIDEO: http://www.newsok.com/article/3634670


..
..Comments for each blog posting are always appreciated. 
     Please use the link found below, to leave comments.. All comments are moderated to reduce SPAM and bad language
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
 Click to: REGISTER For our MS weekly e-Newsletter
"Providing You with 'MS Views and News', IS What We Do"   ~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~ 
Help us to educate $ DONATE NOW PLEASE $

"MS Views and News"  is a 501©(3) Not-For-Profit organization
 as recognized by the Internal Revenue Service

All contributions are tax deductible to the fullest extent allowed by law
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Disclaimer:  'MS Views and News' (MSVN), does not endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.
..............................

1 comment:

Anonymous said...

I am a member of the phase 3 care-ms study and have had the first 5 days of alemtuzemab in june 2011. That was after 2 years in the Rebif group. It is important to note that the drug is only being targeted for use in patients in their first few years following diagnosis and not beyond that point. Something about the disease progression after a few years. It was a 5 day infusion in June and it will be 3 days this coming June. In between I take no meds and no shots. I tolerated the infusion well but drained/hollowed out feeling at the end for a week or so. No new ms problems since the infusion, Rumor is FDA approval may only be months away